4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Duality Biotherapeutics, Inc. (9606) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 266 employees. Its market capitalization is roughly HK$18 billion. In the fiscal year ended 2025-12-31, 9606 reported CNY 1.9B in revenue and (CNY 2.6B) in net income.
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
Interactive charts & full statements → Open the 9606 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 1.9B | CNY 1.9B | CNY 1.8B | CNY 2M |
| Gross Profit | CNY 589M | CNY 785M | CNY 1.4B | CNY 2M |
| Operating Income (EBIT) | (CNY 455M) | (CNY 203M) | CNY 741M | (CNY 370M) |
| Net Income | (CNY 2.6B) | (CNY 1.1B) | (CNY 358M) | (CNY 387M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | CNY 3.9B | CNY 2.1B | CNY 1.5B | CNY 464M |
| Total Liabilities | CNY 1.5B | CNY 4.1B | CNY 2.6B | CNY 1.2B |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9606 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms